Hims & Hers (HIMS) Q2 earnings 2025

Shares of Hims & Hers Health fell 9% in prolonged trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.

Here’s how the corporate did based on average analysts’ estimates compiled by LSEG:

• Earnings per share: 17 cents adjusted vs. 15 cents expected
• Revenue: $544.8 million vs. $552 million expected

Revenue at Hims & Hers increased 73% within the second quarter from $315.6 million through the same period last 12 months, in keeping with a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, in comparison with $13.3 million, or 6 cents per share, through the same period a 12 months earlier.

For its third quarter, Hims & Hers said it expected to report revenue between $570 million and $590 million, while analysts were expecting $583 million. The corporate said its adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, for the quarter might be between the range of $60 million and $70 million. Analysts polled by StreetAccount were expecting $77.1 million.

Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, that are cheaper, unapproved versions of the blockbuster diabetes and weight reduction drugs. Compounded drugs could be mass-produced when brand-name treatments are in shortage, however the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.

Some telehealth firms, including Hims & Hers, have continued to supply the compounded medications. It’s legal for patients to access personalized doses of the knockoffs in unique cases, akin to in the event that they are allergic to an ingredient in a branded product, as an example. Hims & Hers has said consumers should give you the option to access personalized doses through its site if clinically applicable. 

In June, Hims & Hers shares tumbled greater than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers “did not adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.

Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last 12 months and above the $73 million expected by StreetAccount.

Hims & Hers will host its quarterly call with investors at 5 p.m. ET.

— CNBC’s Annika Kim Constantino contributed to this report.